Table 1.
Compound 1 exhibits promising in vitro ADME properties
| Summary of biochemical and ADME properties of 1 | |
|---|---|
| IC50 (μ M) | 0.34 |
| EC50 (VeroE6, SARS-CoV-2) (μ M) | 0.12 |
| Cytotoxicity CC50 (VeroE6) (μ M) | > 10 |
| log D | 0.90 |
| PPB (human, rat) | 68.5%, 58.7% |
| MDCK-MDR1 Papp A-to-B (10−6 cm/s) | 0.20 |
| MDCK-MDR1 Papp B-to-A (10−6 cm/s) | 0.60 |
| MDCK-LE Papp A-to-B (10−6 cm/s) | 0.30 |
| Liver hepatocytes CLint (human, rat) (μg/min/106 cells) | 4.40, 4.00 |
| Liver hepatocytes t1/2 (human, rat) (min) | 158, 172 |
| Liver microsome CLint (human, rat) (μl/min/mg) | < 10.0, < 10.0 |
| Liver microsome t1/2 (human, rat) (min) | > 139, > 139 |
The table shows the measured lipophilicity, plasma protein binding, permeability, and metabolic stability of the compound.